» Articles » PMID: 3258602

Metabolism and Anti-human Immunodeficiency Virus-1 Activity of 2-halo-2',3'-dideoxyadenosine Derivatives

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1988 Apr 25
PMID 3258602
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Both 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine have been shown (Mitsuya, H., and Broder, S. (1987) Nature 325, 773-778) to have in vitro activity against the human immunodeficiency virus-1 (HIV). However, these dideoxynucleosides may be catabolized by human T cells, even when adenosine deaminase is inhibited by deoxycoformycin. To overcome this problem, we have synthesized the 2-fluoro-, 2-chloro-, and 2-bromo-derivatives of 2',3'-dideoxyadenosine. The metabolism and anti-HIV activity of the 2-halo-2',3'-dideoxyadenosine derivatives and of 2',3'-dideoxyadenosine were compared. The 2-halo-2',3'-dideoxyadenosine derivatives were not deaminated significantly by cultured CEM T lymphoblasts. Experiments with 2-chloro-2',3'-dideoxyadenosine showed that the T cells converted the dideoxynucleoside to the 5'-monophosphate, 5'-diphosphate, and 5'-triphosphate metabolites. At concentrations lower than those producing cytotoxicity in uninfected cells (3-10 microM), the 2-halo-2',3-dideoxyadenosine derivatives inhibited the cytopathic effects of HIV toward MT-2 T lymphoblasts, and retarded viral replication in CEM T lymphoblasts. Experiments with a deoxycytidine kinase-deficient mutant CEM T cell line showed that this enzyme was necessary for the phosphorylation and anti-HIV activity of the 2-chloro-2',3'-dideoxyadenosine. In contrast, 2',3'-dideoxyadenosine was phosphorylated by the deoxycytidine kinase-deficient mutant and retained anti-HIV activity in this cell line. Thus, the 2-halo derivatives of 2',3'-dideoxyadenosine, in contrast to 2',3'-dideoxyadenosine itself, are not catabolized by T cells. Their anti-HIV and anti-proliferative activities are manifest only in cells expressing deoxycytidine kinase. The in vivo implications of these results for anti-HIV chemotherapy are discussed.

Citing Articles

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.

Cilento M, Wen X, Reeve A, Ukah O, A Snyder A, Carrillo C Viruses. 2023; 15(10).

PMID: 37896768 PMC: 10612037. DOI: 10.3390/v15101990.


Apigenin improves cytotoxicity of antiretroviral drugs against HTLV-1 infected cells through the modulation of AhR signaling.

Sales D, Lin E, Stoffel V, Dickson S, Khan Z, Beld J NeuroImmune Pharm Ther. 2023; 2(1):49-62.

PMID: 37027342 PMC: 10070013. DOI: 10.1515/nipt-2022-0017.


Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence .

Acosta R, DAntoni M, Mulato A, Yant S, Cihlar T, White K Antimicrob Agents Chemother. 2022; 66(5):e0203821.

PMID: 35389236 PMC: 9112893. DOI: 10.1128/aac.02038-21.


Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.

Cilento M, Reeve A, Michailidis E, Ilina T, Nagy E, Mitsuya H Antimicrob Agents Chemother. 2021; 65(12):e0116721.

PMID: 34516245 PMC: 8597736. DOI: 10.1128/AAC.01167-21.


Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.

Reed J, Solas D, Kitaygorodskyy A, Freeman B, Ressler D, Phuong D J Virol. 2020; 95(3).

PMID: 33148797 PMC: 7925099. DOI: 10.1128/JVI.00883-20.